Patents Assigned to TransTech Pharm, Inc.
  • Patent number: 7776919
    Abstract: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, ?-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.
    Type: Grant
    Filed: January 24, 2008
    Date of Patent: August 17, 2010
    Assignee: TransTech Pharm, Inc.
    Inventors: Adnan M. M. Mjalli, Robert C. Andrews, Ramesh Gopalaswamy, Christopher L. Wysong